Gene Therapies for CMT
Gene therapies are a means to treat disease by modifying the genetic machinery of cells in the body. The goal is to target the underlying genetic cause of disease, which can be accomplished via repair of a genetic defect or replacement of missing or defective genes with healthy, fully functional ones. This in turn enables the normal expression and function of critical proteins.
There are a number of different types of gene therapy. Some of those under development right now include:
- Gene Editing is a precise method of targeting a gene mutation by inserting, removing, or replacing specific pieces of DNA within the faulty gene itself.
- Gene Knockdown, or the reduction of gene expression resulting in reduced protein production, can be achieved during the protein manufacturing process during either transcription or translation via a strategy known as RNA interference (RNAi).
- Gene Replacement is a technique in which the addition of a new, working copy of a gene into target cells serves as a healthy replacement for a missing or mutated gene. The new gene is manufactured in the laboratory and transported to the nucleus of targeted cells, where its code can be read and its instructions for protein production implemented. This type of therapy may be used in loss-of-function disorders caused by a missing or defective gene and the subsequent deficiency or insufficiency of that gene’s normal product. The introduction of the healthy gene is intended to result in production of a sufficient amount of properly functioning protein.
Transportation of genetic material to target cells is an incredibly important part of the gene therapy approach. Small viruses often serve as vectors, or transport vehicles, capable of delivering genetic material “cargo” to its destination either into a cell’s existing DNA or into its nucleus. Many scientists currently are working with adeno-associated viral (AAV) vectors, which are able to penetrate the cell’s nucleus and aren’t known to cause diseases in people. However, their small size limits the amount of genetic material they can carry.
Risks are inherent with any treatment, and gene therapy is no exception. However, it likely won’t be possible to “turn off” gene therapy, which is why it’s critical to study methods of administration, the genetic material to be delivered or altered, a patient’s disease stage and other aspects of his or her genetic makeup.
CMT Research Foundation is leading the charge to ensure safe and effective therapies for all forms of CMT make it to the market to help those living with CMT today. We are working every day to support the families, the foundations, the academics, the scientists, the biotechs and the pharma companies who share our goal and who are working to make it happen.
Related News & Research
CMT2E Gene Therapy Project Successfully Completes Milestone 2
A collaboration between Dr. Chris Lorson and Dr. Michael Garcia of the University of Missouri and funded by the CMT Research Foundation is producing promising results in an innovative new approach to treating CMT2E. CMT2E presents a special challenge in that the...
Italian Research Group Completes CMT Research Foundation-Funded Project, Results Encourage Further Work in New Therapy for Adult and Elderly Patients with CMT1A/CMT1B
The CMT Research Foundation is pleased to announce that Dr. Maurizio D'Antonio's research team at San Raffaele Scientific Institute in Milan, Italy has completed their CMT Research Foundation-funded project investigating the role of a protein called Gadd34 in a mouse...
2022 at CMTRF
Dear Friends of CMTRF, In preparing for another busy year at CMTRF, I took some time recently to look back at the accomplishments of 2022. I am immensely proud of what our team has achieved (summarized below) and I believe it underscores how CMTRF adds significant...
How to Answer: “What is CMT”
By Kenneth Raymond As a patient and an advocate and a student of the condition, I am often asked, “What exactly is CMT?”. My response is usually along the lines of: “CMT stands for Charcot-Marie-Tooth disease, a rare inheritable neuromuscular peripheral neuropathy...
Muscular Dystrophy Association and CMT Research Foundation Announce Joint Research Study Grant
(New York) December 14, 2022 The Muscular Dystrophy Association (MDA) and CMT Research Foundation (CMTRF) announce joint funding for a study by Alessandra Bolino, PhD, at San Raffaele Hospital (Ospedale San Raffaele), Italy, on restoring membrane trafficking in...
Dr. Arthur Suckow, DTx Pharma Inc. – FALCON
One of the first research teams the CMT Research Foundation (CMTRF) funded was DTx Pharma, Inc., and the project focused on delivery of genetic medicine to the myelinating Schwann cells of the peripheral nerves - a major scientific challenge to effectively treating...
Why I Fundraise
My name is Anna and I have CMT1A. I fight for CMT to raise awareness to help others. I fight for CMT to inspire those living with CMT to feel less daunted about the future I fight for CMT to support research for treatments. I fight for CMT to help find a cure. I am...
CMT Research Foundation partners with Samsara Therapeutics to develop a novel class of drugs in CMT1A
The CMT Research Foundation is pleased to announce a new project with Samsara Therapeutics, a US/UK-based biotech company that is developing a novel class of drugs for CMT1A. CMT1A is caused by duplication of a stretch of DNA that includes the PMP22 gene, and people...
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
ATLANTA (October 13, 2022) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease*, has invested in Samsara Therapeutics Inc., a biotech company focusing on discovering and developing...
CMT Research Foundation Awards $152,524 to ORYZON to test novel HDAC6 inhibitors in CMT1A
New project will examine impact of two selective and potent drug candidates recently discovered by ORYZON The CMT Research Foundation is delighted to announce a new project with ORYZON, a clinical stage pharmaceutical company based in Spain. Histone deacetylase (HDAC)...
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy